Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA gives PillCam Colon thumbs down

This article was originally published in The Gray Sheet

Executive Summary

Given Imaging says Feb. 18 it received a "not substantially equivalent" letter from FDA denying its 510(k) application for the PillCam Colon, an ingestible capsule that images the colon. The firm would not disclose details of the letter, but said it is evaluating options to get the device to the U.S. market and is accelerating development of the Colon 2 next-generation capsule. PillCam Colon was approved in Europe in 2006. FDA has cleared PillCam SB 2, for the small bowel, and PillCam ESO 2, for the esophagus. On Feb. 20, Given reported 2007 sales of $112.8 million, a 19% increase over the prior year. The firm's guidance for sales in 2008 is $130 million-$136 million

You may also be interested in...



Given To Launch Next-Gen Colonoscopy PillCam In Europe In November

Given Imaging expects its PillCam COLON 2 endoscopy capsule will overcome many of the limitations identified in a recent clinical trial comparing its first-generation PillCam COLON to standard colonoscopy

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel